Impact of Cardiac Rehabilitation on Metabolic Syndrome in Iranian Patients with Coronary Heart Disease: The Role of Obesity

2012 ◽  
Vol 37 (2) ◽  
pp. 66-73 ◽  
Author(s):  
Ali Kabir ◽  
Nizal Sarrafzadegan ◽  
Afshin Amini ◽  
Reza Safi Aryan ◽  
Fahimeh Habibi Kerahroodi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiac Rehabilitation ◽  
Iranian Patients

Cardiac rehabilitation

2014 ◽  
pp. 323-332
Keyword(s):  
At Risk ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiac Rehabilitation ◽  
Cardiac Disease ◽  
Cardiac Event ◽  
National Service ◽  
National Service Framework ◽  
Service Framework

This chapter looks at the role of cardiac rehabilitation for those at risk of cardiac disease or who have sustained a cardiac event. Cardiac rehabilitation was one of the few areas of the National Service Framework for Coronary Heart Disease where targets were not all met. It is now one of the priority areas for NHS Improvement Heart. A new pathway has been devised for cardiac rehabilitation and this is included here.

scholarly journals Cardiac Rehabilitation Programs Improve Metabolic Parameters in Patients With the Metabolic Syndrome and Coronary Heart Disease

2010 ◽  
Vol 12 (5) ◽  
pp. 374-379 ◽  
Author(s):  
Ignacio P. Pérez ◽  
Maria Á. Zapata ◽  
Carlos E. Cervantes ◽  
Rosario M. Jarabo ◽  
Cristina Grande ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiac Rehabilitation ◽  
Metabolic Parameters ◽  
Rehabilitation Programs ◽  
The Metabolic Syndrome

HIV, Metabolic Syndrome X, Inflammation, Oxidative Stress, and Coronary Heart Disease Risk : Role of Protease Inhibitor Exposure

2004 ◽  
Vol 4 (3) ◽  
pp. 303-316 ◽  
Author(s):  
Barry E. Hurwitz ◽  
Nancy G. Klimas ◽  
Maria M. Llabre ◽  
Kevin J. Maher ◽  
Jay S. Skyler ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Protease Inhibitor ◽  
Coronary Heart Disease Risk ◽  
Disease Risk ◽  
Syndrome X ◽  
Heart Disease Risk

scholarly journals P2554Benefit of cardiac rehabilitation in patients with metabolic syndrome and coronary heart disease

2018 ◽  
Vol 39 (suppl_1) ◽  
Author(s):  
M Trepa ◽  
M Fontes-Oliveira ◽  
R Santos ◽  
R Costa ◽  
A Barreira ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiac Rehabilitation

scholarly journals The action of metformin on the production of pro-inflammatory cytokines and insulin resistance (NF-kB signal pathway)

2012 ◽  
Vol 58 (2) ◽  
pp. 25-28
Author(s):  
A V Lavrenko ◽  
N L Kutsenko ◽  
L A Kutsenko ◽  
T V Mamontova ◽  
I P Kaĭdashev
Keyword(s):  
Metabolic Syndrome ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Inflammatory Cytokines ◽  
Combined Treatment ◽  
Signal Pathway ◽  
Tnf Alpha ◽  
Peptide Level ◽  
Pro Inflammatory Cytokines

The objective of the present study was to estimate the role of the NF-kB signal pathway in the realization of the anti-inflammatory and insulin-synthesizing activities of metformin in the patients presenting with coronary heart disease (CHD) associated with metabolic syndrome (MS). It was shown that the introduction of a one-month course of metformin therapy in the combined treatment of CHD resulted in the decreased production of pro-inflammatory cytokines, such as IL-1-beta, IL-6, IL-8, and TNF-alpha. Simultaneously, the serum C-peptide level decreased. These effects of metformin were mediated through the NF-kB-signal pathway. It is concluded that the inclusion of metformin in the combined treatment of coronary heart disease in the patients with metabolic syndrome prevent activation of NF-kB under the influence of endogeneous pro-inflammatory cytokines.

scholarly journals The significant role of coronary artery calcification score in asymptomatic patients with metabolic syndrome

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
M Temtem ◽  
M Serrao ◽  
M I Mendonca ◽  
M Santos ◽  
J A Sousa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Coronary Heart Disease ◽  
Logistic Regression ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
Coronary Artery Calcification ◽  
Cardiovascular Events

Abstract Background Metabolic syndrome (MetS) is a clinical condition composed of metabolic and cardiovascular risk factors, such as abdominal obesity, hyperglycemia, dyslipidemia and hypertension. Many patients with MetS suffer major adverse cardiovascular events (MACE) that are not adequately identified by traditional risk assessment, suggesting the need for early detection of subclinical coronary heart disease to identify those at high-risk. Coronary artery calcification (CAC) screening has added utility in categorizing patients with low, intermediate and high cardiovascular risk. Purpose Evaluate the prognostic role of CAC score in asymptomatic population patients with metabolic syndrome in cardiovascular events risk prediction. Methods A total of 1,122 asymptomatic individuals without known coronary heart disease, enrolled from GENEMACOR study, were followed for a mean of 5.3±3.4 years for the primary endpoint of all-cause of cardiovascular events. All were referred for computed tomography for the CAC scoring assessment. According to the Hoff's nomogram, 3 categories were created: low CAC (0≤CAC<100 or P<50); moderate CAC (100≤CAC<400 or P50–75) and high or severe CAC (CAC≥400 or P>75). In a subgroup of 507 individuals with MetS and 615 controls, CAC values were compared by T-student and association of CAC severity with events occurrence was evaluated. Finally, a logistic regression model adjusted for CAC severity was performed in patients with MetS. Results Among our population, the extent of CAC differs significantly between men and women in the same age group. Patients with Mets (23.2%, n=115) had higher CAC scores than controls (219.0±486.0 vs 115.8±370.8, p<0.0001). In this cohort, with higher CAC scores, 46.7% vs 22.5% had MACEs (p=0.049) during the follow-up. The logistic regression analysis revealed that CAC≥400 is a MACE predictor (OR=4.326, CI 95% 1.241–15.080, p=0.021) in patients with MetS. Conclusion Our results point to the importance of the inclusion of CAC screening in patients with MetS to further stratify those patients that, despite tight control of cardiovascular risk factors, may benefit from more intensive therapies. This tool is a useful and straightforward method that could have a significant impact on the prognosis of future cardiovascular disease in patients with MetS. FUNDunding Acknowledgement Type of funding sources: None.

Sign in / Sign up

Export Citation Format

Share Document